Gram-positive resistance: Pathogens, implications, and treatment options - Insights from the Society of Infectious Diseases Pharmacists

被引:28
作者
Akins, RL [1 ]
Haase, KK [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharm Practice, Amarillo, TX 79106 USA
来源
PHARMACOTHERAPY | 2005年 / 25卷 / 07期
关键词
gram-positive bacteria; resistance; treatment decisions;
D O I
10.1592/phco.2005.25.7.1001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite the advent of new antibiotics, resistance in gram-positive pathogens, including staphylococci and enterococci, continues to increase. This is evident with the recent emergence of vancomycin-resistant Staphylococcus aureus. Newer treatment agents are available, including quinupristin-dalfopristin, linezolid, and daptomycin. In addition, investigational agents are being explored. Clinical trials have been conducted for various infections, such as skin and skin structure infections, pneumonia, and bloodstream infections. Antibacterial activity, site of infection, and potential for adverse effects must be taken into account when making decisions regarding therapy Key Words: gram-positive bacteria, resistance, treatment decisions.
引用
收藏
页码:1001 / 1010
页数:10
相关论文
共 88 条
[1]   Phenotypic and molecular characterization of community occurring, Western Samoan phage pattern methicillin-resistant Staphylococcus aureus [J].
Adhikari, RP ;
Cook, GM ;
Lamont, I ;
Lang, S ;
Heffernan, H ;
Smith, JMB .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :825-831
[2]   Emergence of a teicoplanin-resistant small colony variant of Staphylococcus epidermidis during vancomycin therapy [J].
Adler, H ;
Widmer, A ;
Frei, R .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (12) :746-748
[3]  
[Anonymous], 2003, M2A8 NAT COMM CLIN L
[4]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[5]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[6]  
[Anonymous], MORB MORTAL WKLY REP
[7]  
[Anonymous], 2004, M100S14 NAT COMM CLI
[8]   SELECTION OF VANCOMYCIN-RESISTANT AND TEICOPLANIN-RESISTANT STAPHYLOCOCCUS-HAEMOLYTICUS DURING TEICOPLANIN TREATMENT OF S-EPIDERMIDIS INFECTION [J].
AUBERT, G ;
PASSOT, S ;
LUCHT, F ;
DORCHE, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (03) :491-493
[9]   Methicillin-resistant Staphylococcus aureus in an adult military beneficiary population lacking risk factors:: Susceptibility to orally available agents [J].
Baum, SE ;
Morris, JT ;
Dooley, DP ;
Watson, R .
MILITARY MEDICINE, 2003, 168 (02) :126-130
[10]   The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans [J].
Bergeron, M ;
Montay, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :129-138